Pilot Study on Trametinib for Surgical Unruptured AVMs
Status:
Recruiting
Trial end date:
2025-11-01
Target enrollment:
Participant gender:
Summary
Arteriovenous malformation (AVM) is a tangle of abnormal vessels that can progress through
life and cause significant bleeding, deformity, pain, and deficits in day-to-day activities.
Surgery is a common treatment option for patients with AVMs where the goal is to safely
remove the entire AVM without causing complications. While any surgery has its potential
risks, most of the potential modifiable risk factors relate to the AVM's structure, such as
the AVM size or presence of high risk structural features seen on scans. The purpose of this
pilot study is to see whether taking an oral medication called Trametinib can improve upon
the AVM structure in adult patients before their scheduled surgery.